We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Seek Interchangeability While Tackling Biosimilars Market
Drugmakers Seek Interchangeability While Tackling Biosimilars Market
March 2, 2012
ORLANDO — Drugmakers are decrying the lack of a clear, accessible path for achieving interchangeability for biosimilars in a recent FDA guidance, saying the designation is critical for the consumer savings that follow-on biologics promise.